St. Luke's Hospital
Main Number: 314-434-1500 Emergency Dept: 314-205-6990 Patient Billing: 888-924-9200
Find a Physician Payment Options Locations & Directions
Follow us on: facebook twitter Mobile Email Page Email Page Print Page Print Page Increase Font Size Decrease Font Size Font Size
Pulmonary Rehabilitation
Pulmonary Function Testing
Respiratory Therapy
Pulmonary Physicians
CardioPulmonary Research Center
St. Luke's Pulmonary Doctors in the News
America's 50 Best Hospitals
Spirit of Women
Community Health Needs Assessment

Pulmonary Services

Pulmonary Fibrosis Study

What is Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a disease of inflammation that results in scarring, or fibrosis, of the lungs. In time, this fibrosis can build up to the point where the lungs are unable to provide oxygen to the tissues of the body. Doctors use the word "idiopathic" (from the Greek "idio" meaning "peculiar" or "unusual" and "pathy" meaning "illness") to describe the disease, because the cause of IPF is unknown. Currently, researchers believe that IPF may result from either an autoimmune disorder, a condition in which the body's immune system attacks its own tissues, or the after effects of an infection, most likely a virus. Whatever the trigger is for IPF, it appears to set off a series of events in which the inflammation and immune activity in the lungs--and, eventually, the fibrosis processes, too--become uncontrollable. In a few cases, heredity appears to play a part, possibly making some individuals more likely than others to get IPF. In studies of patients with IPF, the average survival rate has been found to be 4 to 6 years after diagnosis. Those who develop IPF at a young age seem to have a longer survival.

MedImmune: a Phase 2, Randomized Dose-ranging Study up to 68 weeks of treatment to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis.

PANTHER: a one-year study testing Prednisone, N-acetylcysteine and Azathioprine to evaluate its effect on IPF. -Closed to enrollment

FIBROGEN: a 45-week study to determine the safety of FG-3019 in subjects with IPF. (Idiopathic Pulmonary Fibrosis) -Closed to enrollment

BIPI 1199.34: a 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline, in patients with Idiopathic Pulmonary Fibrosis (IPF). -Closed to enrollment

PIPF-016: a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Learn more about the Intermune study. -Closed to enrollment

ROCHE: a new injectable study drug given every 4 weeks to slow the progression of IPF, study could last from 1 to 2.5 years.

RAINIER: a placebo controlled study involving new weekly injectable drug (GS-6624) to slow the progression of IPF, study could last up to 3-1/2 yrs.

BMS: a study involving a new oral medication to reduce the rate of decline in your forced vital capacity (FVC). Study will last approximately 34 weeks.

All qualified participants will receive at no cost, study related physical exam, medical care and medications.

If you are interested in the study or more information, contact the CardioPulmonary Research Center at 314-439-LUNG (5864).

Dr. Ettinger: Idiopathic Pulmonary Fibrosis (IPF)

Back  |  Top
About Us
Contact Us
Locations & Directions
Quality Reports
Annual Reports
Honors & Awards
Community Health Needs

Brain & Spine
Sleep Medicine
Urgent Care
Women's Services
All Services
Patients & Visitors
Locations & Directions
Find a Physician
Tour St. Luke's
Patient & Visitor Information
Contact Us
Payment Options
Financial Assistance
Send a Card
Mammogram Appointments
Health Tools
My Personal Health
Spirit of Women
Health Information & Tools
Clinical Trials
Health Risk Assessments
Employer Programs -
Passport to Wellness

Classes & Events
Classes & Events
Spirit of Women
Donate & Volunteer
Giving Opportunities
Physicians & Employees
For Physicians
Remote Access
Medical Residency Information
Pharmacy Residency Information
Physician CPOE Training
St. Luke's Hospital - 232 South Woods Mill Road - Chesterfield, MO 63017 Main Number: 314-434-1500 Emergency Dept: 314-205-6990 Patient Billing: 888-924-9200
Copyright © St. Luke's Hospital Website Terms and Conditions  |  Privacy Policy  |  Patient Notice of Privacy Policies PDF Sitemap St. Luke's Mobile